Dinutuximab: First global approval

Drugs

Volumn 75, Issue 8, 2015, Pages 923-927

  Dhillon, Sohita ^a  

^a Mairangi Bay   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; DINUTUXIMAB; GANGLIOSIDE GD2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G1; INTERLEUKIN 2; ISOTRETINOIN; ANTINEOPLASTIC AGENT; GANGLIOSIDE; GANGLIOSIDE, GD2; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CHILDHOOD CANCER; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG APPROVAL; DRUG HYPERSENSITIVITY; DRUG MARKETING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEVER; HIGH RISK PATIENT; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INFECTION; NEUROBLASTOMA; NEUROPATHIC PAIN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT RESPONSE; ANIMAL; CHILD; FOOD AND DRUG ADMINISTRATION; IMMUNOLOGY; PATHOLOGY; UNITED STATES;

MURINAE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; DRUG APPROVAL; GANGLIOSIDES; HUMANS; NEUROBLASTOMA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84930177401     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0399-5     Document Type: Article

References (25)

1. Hara J. Development of treatment strategies for advanced neuroblastoma. Int J Clin Oncol. 2012;17(3):196-203.
2. Castel V, Segura V, Canete A. Treatment of high-risk neuroblastoma with anti-GD2 antibodies. Clin Transl Oncol. 2010;12(12):788-93.
3. Parsons K, Bernhardt B, Strickland B. Targeted immunotherapy for high-risk neuroblastoma: the role of monoclonal antibodies. Ann Pharmacother. 2013;47(2):210-8.
4. Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 2014;588(2):288-97.
5. Mueller BM, Romerdahl CA, Gillies SD, et al. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol. 1990;144(4):1382-6.
6. United Therapeutics Corporation. Unituxin™: US prescribing information. 2015. http://www.accessdata.fda.gov/drugsatfda-docs/label/2015/125516s000lbl.pdf. Accessed 25 Mar 2015.
7. US Food and Drug Administration. Dinutuximab. 2015. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm437480.htm. Accessed 16 Mar 2015.
8. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324-34.
9. Albertini MR, Hank JA, Schiller JH, et al. Phase Ib trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res. 1997;3(8):1277-88.
10. Murray JL, Kleinerman ES, Jia SF, et al. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma. J Immunother. 1996;19(3):206-17.
11. Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas. 1992;3(1):19-24.
12. Choi BS, Sondel PM, Hank JA, et al. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother. 2006;55:761-74.
13. United Therapeutics Corporation. United therapeutics receives a rare pediatric disease priority review voucher following the approval of Unituxin™ for pediatric high-risk neuroblastoma (media release). 2015. http://ir.unither.com/releasedetail.cfm?ReleaseID=900822.
14. Department of Health and Human Services. BLA 125516 (BLA approval). 2015. http://www.accessdata.fda.gov/drugsatfda-docs/appletter/2015/125516Orig1s000ltr.pdf. Accessed 1 Apr 2015.
15. Barker E, Mueller BM, Handgretinger R, et al. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res. 1991;51(1):144-9.
16. Uttenreuther-Fischer MM, Huang CS, Yu AL. Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients. Cancer Immunol Immunother. 1995;41(6):331-8.
17. Desai AV, Fox E, Smith LM, et al. Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. Cancer Chemother Pharmacol. 2014;74(5):1047-55.
18. Ozkaynak MF, Gilman AL, Yu AL, et al. A comprehensive safety trial of chimeric antibody 14.18 (ch14.18) with GM-CSF, IL-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: a Children's Oncology Group study (abstract no. 10044). J Clin Oncol. 2014;32(15 Suppl 1).
19. Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer. 1995;31a(2):261-7.
20. Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol. 1998;16(6):2169-80.
21. Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-ganglioside GD2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol. 2000;18(24):4077-85.
22. Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol. 2009;27(1):85-91.
23. Simon T, Hero B, Faldum A, et al. Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy. Klin Padiatr. 2005;217(3):147-52.
24. Simon T, Hero B, Faldum A, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol. 2004;22(17):3549-57.
25. Simon T, Hero B, Faldum A, et al. Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer. 2011;11:21.